OSE Immunotherapeutics SA Profile Avatar - Palmy Investing

OSE Immunotherapeutics SA

OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of no…

Biotechnology
FR, Nantes [HQ]
Financials

Analysts

Earnings
Reported
Past Estimate Consensus
Future Estimate Consensus
OSE Immunotherapeutics SA can't present any analysts estimates at the moment detail analysis.
Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Overall Consensus
Grading Consensus
Click to each, to see the grade
OSE Immunotherapeutics SA can't present the grade consensus distribution right now.
Price Target Consensus
Price Then
$n/a
Price Target
$n/a
Price Now
$7.10
End of OSE.PA's Analysis
CIK: - CUSIP: F6913C100 ISIN: FR0012127173 LEI: - UEI: -
Secondary Listings
OSE.PA has no secondary listings inside our databases.